Tackling non-muscle invasive bladder cancer in the clinic

Solomon L. Woldu, Oner Mehmet Sanli, Yair Lotan

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC–which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG). As many patients will be resistant to conventional treatment, investigational therapies and novel prognostic models will also be discussed. Expert commentary: For decades, the management of NMIBC has been predicated on intravesical therapies, most often through the instillation of BCG which has proven clinical efficacy over transurethral resection alone. Despite this, many patients will recur or progress after BCG therapy. While radical cystectomy remains the standard for such patients, suitable alternatives are being actively investigated. An increased interest in immunotherapy for malignancy has reinvigorated this field and on-going advances in disease prognostication are likely to improve upon the existing treatment paradigms for NMIBC.

Original languageEnglish (US)
Pages (from-to)467-480
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume17
Issue number5
DOIs
StatePublished - May 4 2017

Fingerprint

Urinary Bladder Neoplasms
Mycobacterium bovis
Immunotherapy
Therapeutics
Investigational Therapies
Cystectomy
Neoplasms
Guidelines
Recurrence
Drug Therapy
Muscles

Keywords

  • BCG
  • chemothermotherapy
  • electromotive drug administration
  • intravesical therapy
  • Non-muscle invasive bladder cancer
  • novel

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Tackling non-muscle invasive bladder cancer in the clinic. / Woldu, Solomon L.; Sanli, Oner Mehmet; Lotan, Yair.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 5, 04.05.2017, p. 467-480.

Research output: Contribution to journalReview article

@article{be0f14e8052f4b5890349a84eeff92d9,
title = "Tackling non-muscle invasive bladder cancer in the clinic",
abstract = "Introduction: Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC–which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG). As many patients will be resistant to conventional treatment, investigational therapies and novel prognostic models will also be discussed. Expert commentary: For decades, the management of NMIBC has been predicated on intravesical therapies, most often through the instillation of BCG which has proven clinical efficacy over transurethral resection alone. Despite this, many patients will recur or progress after BCG therapy. While radical cystectomy remains the standard for such patients, suitable alternatives are being actively investigated. An increased interest in immunotherapy for malignancy has reinvigorated this field and on-going advances in disease prognostication are likely to improve upon the existing treatment paradigms for NMIBC.",
keywords = "BCG, chemothermotherapy, electromotive drug administration, intravesical therapy, Non-muscle invasive bladder cancer, novel",
author = "Woldu, {Solomon L.} and Sanli, {Oner Mehmet} and Yair Lotan",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14737140.2017.1313119",
language = "English (US)",
volume = "17",
pages = "467--480",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Tackling non-muscle invasive bladder cancer in the clinic

AU - Woldu, Solomon L.

AU - Sanli, Oner Mehmet

AU - Lotan, Yair

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC–which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG). As many patients will be resistant to conventional treatment, investigational therapies and novel prognostic models will also be discussed. Expert commentary: For decades, the management of NMIBC has been predicated on intravesical therapies, most often through the instillation of BCG which has proven clinical efficacy over transurethral resection alone. Despite this, many patients will recur or progress after BCG therapy. While radical cystectomy remains the standard for such patients, suitable alternatives are being actively investigated. An increased interest in immunotherapy for malignancy has reinvigorated this field and on-going advances in disease prognostication are likely to improve upon the existing treatment paradigms for NMIBC.

AB - Introduction: Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC–which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG). As many patients will be resistant to conventional treatment, investigational therapies and novel prognostic models will also be discussed. Expert commentary: For decades, the management of NMIBC has been predicated on intravesical therapies, most often through the instillation of BCG which has proven clinical efficacy over transurethral resection alone. Despite this, many patients will recur or progress after BCG therapy. While radical cystectomy remains the standard for such patients, suitable alternatives are being actively investigated. An increased interest in immunotherapy for malignancy has reinvigorated this field and on-going advances in disease prognostication are likely to improve upon the existing treatment paradigms for NMIBC.

KW - BCG

KW - chemothermotherapy

KW - electromotive drug administration

KW - intravesical therapy

KW - Non-muscle invasive bladder cancer

KW - novel

UR - http://www.scopus.com/inward/record.url?scp=85018638825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018638825&partnerID=8YFLogxK

U2 - 10.1080/14737140.2017.1313119

DO - 10.1080/14737140.2017.1313119

M3 - Review article

C2 - 28359179

AN - SCOPUS:85018638825

VL - 17

SP - 467

EP - 480

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -